中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.011 seconds)

    METHODS AND COMPOSITIONS FOR VIRAL VECTORED VACCINES
    1.
    发明申请
    METHODS AND COMPOSITIONS FOR VIRAL VECTORED VACCINES 审中-公开
    用于病毒感染的疫苗的方法和组合物

    公开(公告)号：WO2015035128A1

    公开(公告)日：2015-03-12

    申请号：PCT/US2014/054234

    申请日：2014-09-05

    Applicant: VAXIN INC. ,  TANG, De-chu

    Inventor： TANG, De-chu

    IPC: A61K39/12 ,  A61K39/23 ,  A61K45/00

    CPC classification number: A61K39/12 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55561 ,  C12N2710/10343 ,  C12N2760/16134

    Abstract: Methods and compositions are provided herein for non-invasive administration of an adenoviral vector (Ad-vector) vaccine with an adjuvant, such as a TLR3 agonist. These methods provide, for example, an increase in the immune response to the vaccine, an increase in the immunogenicity of the Ad-vector vaccine, an antigen sparing effect and improved safety with an effective protective immune response to the vaccine.

    Abstract translation: 本文提供了用佐剂例如TLR3激动剂非侵入性施用腺病毒载体（Ad载体）疫苗的方法和组合物。 这些方法例如提供对疫苗的免疫应答的增加，Ad-载体疫苗的免疫原性的增加，抗原的保护作用以及改进的对疫苗的有效保护性免疫应答的安全性。

    INTRANASAL ADMINISTRATION OF RECEPTOR-BINDING LIGANDS OR GENES ENCODING SUCH LIGANDS
    2.
    发明申请
    INTRANASAL ADMINISTRATION OF RECEPTOR-BINDING LIGANDS OR GENES ENCODING SUCH LIGANDS 审中-公开
    受体结合配偶或编码此类配体的基因的内分泌管理

    公开(公告)号：WO2010044921A3

    公开(公告)日：2010-07-15

    申请号：PCT/US2009046132

    申请日：2009-06-03

    Applicant: VAXIN INC ,  TANG DE-CHU C ,  VAN KAMPEN KENT R

    Inventor： TANG DE-CHU C ,  VAN KAMPEN KENT R

    IPC: A61K39/12 ,  A61K39/145 ,  A61K39/235

    CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/145 ,  A61K39/215 ,  A61K2039/543 ,  A61K2039/58 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16234 ,  C12N2770/20022

    Abstract: The present invention relates to a receptor-binding ligand either administered intranasally or expressed following intranasal administration from a recombinant vector that expresses at least one therapeutic ligand which binds to a receptor necessary for infection by a respiratory pathogen. The receptor-binding ligand in the respiratory tract not only confers rapid protection as a therapeutic drug but also elicits long-term protective immunity as a vaccine against a respiratory pathogen. This regimen is not compromised by the emergence of drug resistance because the receptor for any pathogen can be blocked by the pathogen's own receptor-binding ligand.

    Abstract translation: 本发明涉及一种受体结合配体，其通过鼻内施用从表达至少一种结合受呼吸道病原体感染所必需的受体的治疗配体的重组载体进行鼻内施用或表达。 呼吸道中的受体结合配体不仅赋予作为治疗药物的快速保护作用，而且引发作为针对呼吸道病原体的疫苗的长期保护性免疫。 这种方案不会因耐药性的出现而受损，因为任何病原体的受体可被病原体自身的受体结合配体阻断。

    RAPID AND PROLONGED IMMUNOLOGIC-THERAPEUTIC
    4.
    发明申请
    RAPID AND PROLONGED IMMUNOLOGIC-THERAPEUTIC 审中-公开
    快速和全面的免疫治疗

    公开(公告)号：WO2012129295A1

    公开(公告)日：2012-09-27

    申请号：PCT/US2012/029927

    申请日：2012-03-21

    Applicant: VAXIN INC. ,  TANG, De-chu, C.

    Inventor： TANG, De-chu, C.

    IPC: A61K39/23

    CPC classification number: C12N15/86 ,  A61K39/00 ,  A61K39/07 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/543 ,  A61K2039/58 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2760/16134

    Abstract: The present invention shows that intranasal administration of E1/E3 -defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the El/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3 -defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).

    Abstract translation: 本发明表明，E1 / E3-有效腺病毒颗粒的鼻内施用可以在各种疾病环境中对病毒和细菌病原体进行快速和广泛的保护。 在动物模型中，单剂量方案的保护作用持续了数周。 当将病原体衍生的抗原基因插入E1 / E3缺陷型腺病毒基因组中时，在腺病毒介导的保护性反应下降之前引发抗原诱导的特异性病原体的保护性免疫，从而赋予快速，延长和无缝保护 针对病原体。 除E1 / E3-有效腺病毒外，编码病原体衍生抗原的其他生物工程非复制载体也可以发展成新一代快速和延长的免疫治疗（RAPIT）。

    TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
    8.
    发明申请
    TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH 审中-公开
    使用重组子宫颈癌进行性行为和/或功能的瞬时和/或永久性修改

    公开(公告)号：WO2003089590A2

    公开(公告)日：2003-10-30

    申请号：PCT/US2003/011590

    申请日：2003-04-16

    Applicant: VAXIN, INC. ,  BAKER, Henry, ,  TANG, De-chu, C. ,  VAN KAMPEN, Kent, Rigby

    Inventor： BAKER, Henry, ,  TANG, De-chu, C. ,  VAN KAMPEN, Kent, Rigby

    IPC: C12N

    CPC classification number: C07K7/23 ,  A61K38/09 ,  A61K48/00 ,  C07K2317/00 ,  C07K2319/00

    Abstract: The invention provides an immunogenic composition comprising a GnRH multimer and an antigenic carrier, an immunogenic composition comprising a recombinant vector containing a nucleic acid molecule encoding a GnRH multimer and optionally an antigenic carrier, antibodies elicited by the immunogenic compositions, and methods of using the immunogenic compositions and antibodies for modifying sexual physiology and behavior, improving the organoleptic properties of meat, and treating androgen-dependent prostate tumors and GnRH-sensitive ovarian tumors.

    Abstract translation: 本发明提供了包含GnRH多聚体和抗原载体的免疫原性组合物，包含含有编码GnRH多聚体和任选的抗原载体的核酸分子的重组载体的免疫原性组合物，由免疫原性组合物引发的抗体，以及使用免疫原性 用于改变性生理和行为的组合物和抗体，改善肉的感官特性，以及治疗雄激素依赖性前列腺肿瘤和GnRH敏感性卵巢肿瘤。

Patent Agency Ranking